As shown in Figure 4, CD14 positivity increased significantly in the NASH group when compared with the control group (60.00 ± 9.00 vs. 14 ± 3.00, respectively; p < 0.05). This evidence concerns the gene CD14 and metabolic dysfunction-associated steatohepatitis.